Low-Risk Differentiated Thyroid Cancer and Radioiodine Remnant Ablation: A Systematic Review of the Literature | Zendy

Livia Lamartina | Zendy; Cosimo Durante | Zendy; Sébastiano Filetti | Zendy; David S. Cooper | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Low-Risk Differentiated Thyroid Cancer and Radioiodine Remnant Ablation: A Systematic Review of the Literature

Author(s) -

Livia Lamartina,

Cosimo Durante,

Sébastiano Filetti,

David S. Cooper

Publication year - 2015

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2014-3882

Subject(s) - medicine , thyroglobulin , thyroid cancer , thyroid , pathological , cancer , oncology , surgery , endocrinology

Radioiodine remnant ablation (RRA) has traditionally been one of the cornerstones of differentiated thyroid cancer (DTC) treatment. The decision to use RRA in low-risk (LR) and intermediate-risk (IR) patients is controversial. The aim of this review is to examine the evidence of RRA benefit in the staging, follow-up, and recurrence prevention in LR and IR DTC patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research